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Abstract There is mounting evidence that microbes residing in the human intestine contribute
to diverse alcohol-associated liver diseases (ALD) including the most deadly form known as alcohol-
associated hepatitis (AH). However, mechanisms by which gut microbes synergize with excessive
alcohol intake to promote liver injury are poorly understood. Furthermore, whether drugs that
selectively target gut microbial metabolism can improve ALD has never been tested. We used liquid
chromatography tandem mass spectrometry to quantify the levels of microbe and host choline
co-metabolites in healthy controls and AH patients, finding elevated levels of the microbial metabolite trimethylamine (TMA) in AH. In subsequent studies, we treated mice with non-lethal bacterial
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choline TMA lyase (CutC/D) inhibitors to blunt gut microbe-dependent production of TMA in the
context of chronic ethanol administration. Indices of liver injury were quantified by complementary RNA sequencing, biochemical, and histological approaches. In addition, we examined the
impact of ethanol consumption and TMA lyase inhibition on gut microbiome structure via 16S rRNA
sequencing. We show the gut microbial choline metabolite TMA is elevated in AH patients and
correlates with reduced hepatic expression of the TMA oxygenase flavin-containing monooxygenase
3 (FMO3). Provocatively, we find that small molecule inhibition of gut microbial CutC/D activity
protects mice from ethanol-induced liver injury. CutC/D inhibitor-driven improvement in ethanol-
induced liver injury is associated with distinct reorganization of the gut microbiome and host liver
transcriptome. The microbial metabolite TMA is elevated in patients with AH, and inhibition of TMA
production from gut microbes can protect mice from ethanol-induced liver injury.

Editor's evaluation
This paper aims to understand the mechanisms by which gut microbes synergize with excessive
alcohol intake to cause liver injury, and whether drugs that selectively target gut microbial metabolism can improve alcohol-associated liver disease (ALD). The authors used liquid chromatography
tandem mass spectrometry to quantify the levels of microbe and host choline co-metabolites in
controls and patients with alcohol-associated hepatitis (AH). They also treated mice with bacterial
choline trimethylamine (TMA) lyase inhibitors to reduce gut microbe-dependent TMA production, followed by measurement of Indices of liver injury. They showed that gut microbial choline
metabolite TMA is increased in AH patients, which correlates with reduced liver expression of the
TMA oxygenase Flavin-containing monooxygenase 3 (FMO3). They also show that inhibition of gut
microbial CutC/D activity protects from ethanol-induced liver injury in mouse models, which was
associated with reorganization of the gut microbiome and host liver transcriptome. The authors
conclude that microbial TMA is elevated in patients with AH, and inhibition of TMA production by
gut microbes protects against ethanol-induced liver injury.

Introduction
Alcohol-associated liver disease (ALD) includes a spectrum of liver pathologies including steatosis,
fibrosis, cirrhosis, and the most severe manifestation known as alcohol-associated hepatitis (AH).
Shortly after diagnosis AH patients die at a staggering rate of 40–50% (Masarone et al., 2016;
Kochanek et al., 2017). Despite many attempts, an effective therapy for this deadly disease has
been elusive. Similar to other components of the spectrum of ALD, AH has consistently been linked
to reorganization of the gut microbiome and dysregulation of microbe-host interactions (Chen et al.,
2011; Yan et al., 2011; Mutlu et al., 2009; Mutlu et al., 2012; Tripathi et al., 2018; Ciocan et al.,
2018; Llopis et al., 2016; Duan et al., 2019; Smirnova et al., 2020; Gao et al., 2019; Puri et al.,
2018; Lang and Schnabl, 2020). It is well appreciated that chronic alcohol use can elicit structural
alterations in the gut barrier, allowing either live bacteria themselves or microbe-associated molecule
patterns (MAMPs), such as lipopolysaccharide (LPS), to enter the portal circulation where they can
directly engage pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) or NOD-like
receptors (NLRP3, NLRP6, etc.) to promote hepatic inflammation and tissue injury (Wilkinson et al.,
1974; Tarao et al., 1979; Uesugi et al., 2001; Paik et al., 2003; DeSantis et al., 2013; Knorr et al.,
2020). In addition to MAMP-PRR interactions, gut microbes can act as a collective endocrine organ,
producing a vast array of small molecules, proteins, and lipid metabolites that can engage dedicated
host receptor systems to also impact liver disease progression (Brown and Hazen, 2015). Collectively,
these MAMP-PRR and microbial metabolite-host receptor interactions converge to promote ALD and
many other diseases of uncontrolled inflammation (Brown and Hazen, 2015; Gilbert et al., 2018).
Although there is now clear evidence that microbe-host interactions play a key role in liver disease
progression (Chen et al., 2011; Yan et al., 2011; Mutlu et al., 2009; Mutlu et al., 2012; Tripathi et al.,
2018; Ciocan et al., 2018; Llopis et al., 2016; Duan et al., 2019; Smirnova et al., 2020; Gao et al.,
2019; Puri et al., 2018; Lang and Schnabl, 2020; Wilkinson et al., 1974; Tarao et al., 1979; Uesugi
et al., 2001; Paik et al., 2003; DeSantis et al., 2013; Knorr et al., 2020; Brown and Hazen, 2015;
Gilbert et al., 2018), ALD drug discovery to this point has focused primarily on targets encoded by the
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human genome. Our knowledge is rapidly expanding as to how microbes intersect with ALD progression, including cataloging microbial genomes. We also now understand the repertoire of MAMPs gut
microbes harbor as well as the vast array of metabolites that they produce in both patients with ALD
and animal models of ethanol-induced liver injury (Chen et al., 2011; Yan et al., 2011; Mutlu et al.,
2009; Mutlu et al., 2012; Tripathi et al., 2018; Ciocan et al., 2018; Llopis et al., 2016; Duan et al.,
2019; Smirnova et al., 2020; Gao et al., 2019; Puri et al., 2018; Lang and Schnabl, 2020; Wilkinson
et al., 1974; Tarao et al., 1979; Uesugi et al., 2001; Paik et al., 2003; DeSantis et al., 2013; Knorr
et al., 2020; Brown and Hazen, 2015; Gilbert et al., 2018). However, there are very few examples of
where this information has been leveraged into safe and effective therapeutic strategies. In general,
the microbiome-targeted therapeutic field has primarily focused on either anti-, pre-, or pro-biotic
approaches, yet these microbial community-restructuring approaches have resulted in very modest or
non-significant effects in clinical studies of liver disease (Kwak et al., 2014; Asgharian et al., 2020;
Reijnders et al., 2016; Madjd et al., 2016). As an alternative microbiome-targeted approach, we and
others have begun developing non-lethal selective small molecule inhibitors of bacterial enzymes with
the intention of reducing levels of disease-associated microbial metabolites with mechanistic rationale
for contribution to disease pathogenesis (Roberts et al., 2018; Wang et al., 2015; Gupta et al.,
2020; Organ et al., 2020; Orman et al., 2019). In fact, we have recently shown that small molecule
inhibition of the gut microbial transformation of choline into trimethylamine (TMA), the initial and
rate-limiting step in the generation of the cardiovascular disease (CVD)-associated metabolite trimethylamine N-oxide (TMAO), can significantly reduce disease burden in animal models of atherosclerosis, thrombosis, heart failure, and chronic kidney disease (Roberts et al., 2018; Wang et al., 2015;
Gupta et al., 2020; Organ et al., 2020). Although the gut microbial TMAO pathway has been studied
mostly in the context of CVD (Wang et al., 2011; Koeth et al., 2013; Zhu et al., 2016; Zhu et al.,
2017; Tang et al., 2013; Wang et al., 2014b; Trøseid et al., 2015; Tang and Hazen, 2014), recent
studies found that breath levels of the primary metabolite TMA and other related co-metabolites
are elevated in patients with ALD (Hanouneh et al., 2014; Ascha et al., 2016). These data showed
promise, but whether the gut microbial TMAO pathway is causally related to ALD has never been
explored. Hence, here we set out to understand how the gut microbial TMA/TMAO pathway may
play a contributory role in ALD susceptibility and progression, and to test whether selective drugs that
lower gut microbial production of TMA can be an effective therapeutic strategy. In an era when host
genetics/genomics approaches dominate, this work reminds us that genes and metabolic products
produced by gut bacteria play equally important roles in modulating disease susceptibility. Whereas
pathways encoded by the host genome have long been pursued as drug targets, this work provides
proof of concept that rationally designed drugs that target bacterial metabolism likely have untapped
therapeutic potential in ALD and beyond.

Results
Circulating levels of the gut microbial metabolite TMA are elevated in
AH
In a previous collaborative study, we reported that the highly volatile microbial metabolite TMA is
elevated in exhaled breath of patients with AH (Hanouneh et al., 2014), and related co-metabolites,
such as trimethyllysine and carnitine, can serve as prognostic indicators of mortality in AH (Ascha et al.,
2016). Given the extremely volatile nature of TMA, it is readily detectable in breath, but is challenging
to accurately quantitate levels in the circulation because TMA rapidly dissipates during collection
and storage. To reduce the volatility of TMA and enable its analysis in the circulation, we coordinated
patient blood collection utilizing rapid acidification of separated plasma (protonated TMA has a lower
vapor pressure) across a large multi-center AH consortium (Defeat Alcoholic Steatohepatitis [DASH]
consortium) (Crabb et al., 2016; Vatsalya et al., 2020; Saha et al., 2019). This provided us the
unique opportunity to accurately quantify circulating TMA levels in human subjects, including those
with moderate or severe AH for the first time. Patient demographics and clinical characteristics for the
cohort examined are summarized in Figure 1—source data 1; Figure 1—source data 2. Importantly,
MELD score, Maddrey’s discriminant function score, Child-Pugh score, aspartate aminotransferase
(AST), total bilirubin, creatinine, and international normalized ratio were higher in patients with severe
AH compared to moderate AH patients, while serum albumin was lower in severe AH compared to
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moderate AH patients. In agreement with previous breath metabolomics studies (Hanouneh et al.,
2014; Ascha et al., 2016), plasma TMA levels were significantly elevated in moderate and severe AH
patients compared to healthy controls (Figure 1A). However, the CVD-related co-metabolite TMAO
was reciprocally decreased in AH patients (Figure 1B). Given the reciprocal alterations in plasma TMA
and TMAO levels, we next examined the expression of the host liver enzyme flavin-containing monooxygenase 3 (FMO3) which is the predominant TMA to TMAO converting enzyme in the adult liver
(Cashman, 2002). Interestingly, mRNA levels for FMO3 are uniquely repressed in patients with more
severe AH (AH with liver failure [MELD 22–28] and AH with emergency liver transplant [MELD 18–21]),
but not in other liver disease etiologies such as non-alcoholic fatty liver disease (NAFLD) or viral
hepatitis (Figure 1C). In agreement with reduced mRNA levels (Figure 1C), patients with severe AH
undergoing emergency liver transplant have marked reduction in FMO3 protein (Figure 1D), which
likely contributes to elevations in plasma TMA (Figure 1A). Although ethanol feeding in mice does
not consistently result in reduced hepatic Fmo3 expression (data not shown), a single injection of lipopolysaccharide (LPS) to induce acute hepatic inflammation is associated with both a reduction in the
expression of Fmo3 and a significant increase in the TMA receptor trace amine-associated receptor 5
(Taar5) (Figure 1E). It is important to note that circulating choline levels was not significantly altered
in patients with AH compared to healthy controls (Figure 1—figure supplement 1). However, plasma
levels of one of the gut microbial substrates for TMA production (carnitine) and other TMA pathway
co-metabolites (e.g. betaine and γ-butyrobetaine) were elevated in patients with AH compared to
healthy controls (Figure 1—figure supplement 1). These findings, in addition to previous breath
metabolomic studies (Hanouneh et al., 2014; Ascha et al., 2016), provide evidence that TMA and
related co-metabolites may allow for discrimination of AH from other liver diseases.

Microbial choline TMA lyase inhibition protects mice from ethanolinduced liver injury
We next sought to establish whether a causal relationship between gut microbial TMA production and
ALD progression exists, and to test the hypothesis that selectively drugging microbial choline transformation can serve as a mechanism for improving host liver disease and attenuating ethanol-induced
liver injury in mice. Mice were individually treated with two recently reported non-lethal bacterial
choline TMA lyase inhibitors, iodomethylcholine (IMC) and fluoromethylcholine (FMC) (Roberts et al.,
2018). These small molecule inhibitors exhibit potent in vivo inhibition of the gut microbial choline
TMA lyase enzyme CutC (Craciun and Balskus, 2012), and have been shown to effectively block
bacterial choline to TMA conversion in vivo (Roberts et al., 2018). Designed as suicide substrate
mechanism-based inhibitors, past studies reveal that the vast majority of IMC and FMC is retained in
the gut within luminal bacteria and excreted in the feces with limited systemic exposure of the polar
drug in the host (Roberts et al., 2018; Gupta et al., 2020; Organ et al., 2020).
IMC treatment effectively blunted ethanol-induced increases in plasma TMA and TMAO (Figure 2A
and B). IMC also produced modest increases in plasma choline and betaine, while reducing plasma
carnitine, particularly in pair-fed mice (Figure 2C–E). IMC also prevented ethanol-induced increases
in alanine aminotransferase (ALT) and hepatic steatosis (Figure 2F, G, and K). Interestingly, IMC
treatment prevented ethanol-induced increases in hepatic triglycerides (Figure 2G), and reduced
hepatic total and cholesterol esters, but not free cholesterol, in both pair- and ethanol-fed conditions
(Figure 2H–I). IMC treatment also reduced the expression levels of the pro-inflammatory cytokine
tumor necrosis factor α (Tnfα) (Figure 2L). Although IMC was well tolerated in several previous mouse
studies in the setting of standard rodent chow-feeding (Roberts et al., 2018; Gupta et al., 2020;
Organ et al., 2020), here we found an unexpected reduction in food intake and body weights in mice
receiving both IMC and ethanol (Figure 2—figure supplement 1A, B). Although IMC was clearly
protective against ethanol-induced liver injury, this potential drug-ethanol interaction prompted us
to test another structurally distinct gut microbe-targeted choline TMA lyase inhibitor FMC (Roberts
et al., 2018; Figure 3 and Figure 3—figure supplement 1).
Importantly, FMC was well tolerated and did not significantly alter liquid diet intake or body
weights throughout the 25-day chronic ethanol feeding study (Figure 2—figure supplement 1C, D).
FMC treatment trended toward reducing plasma TMA (Figure 3A), and more dramatically suppressed
plasma TMAO levels (Figure 3B). Unlike IMC, which also altered other co-metabolites such as choline,
betaine, and carnitine (Figure 2B-E), FMC did not significantly alter these TMA co-
metabolites
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Figure 1. The gut microbial volatile metabolite trimethylamine (TMA) is elevated in alcohol-associated hepatitis
(AH). Plasma TMA (A) and trimethylamine N-oxide (TMAO) (B) levels in patients considered healthy (n = 13 for TMA
and 20 for TMAO), or who have moderate (MELD < 20) (n = 52 for TMA and 111 for TMAO) or severe (MELD >
20) (n = 83 for TMA and 152 for TMAO) AH. (C) RNA sequencing results from liver tissues of patients with different
Figure 1 continued on next page
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pathologies, including: healthy controls (HC, n = 10), early AH (EAH, n = 12; MELD 7–8), AH with liver failure (AHL,
n = 18; MELD 22–28), explant tissue from patients with severe AH with emergency liver transplants (ExAH, n = 10;
MELD 18–21), non-alcohol-associated fatty liver disease (NAFLD; n = 8), hepatitis C virus (HCV; n = 9), and hepatitis
C virus with cirrhosis (HCV_Cirr, n = 9). Gene expression was measured by transcripts per million (TPM). Boxplots
of average expression for Fmo3 in different disease groups; error bars indicate SD (q < 0.05 in comparison to
healthy controls). (D) Liver FMO3 protein expression measured by Western blot from healthy patients and patients
with severe AH undergoing emergency liver transplant (Maddrey’s discriminant function 45–187). (E) Liver Tnfa,
Il1b, Fmo3, and Taar5 transcript levels were measured by qPCR from female WT mice injected with either saline or
lipopolysaccharide (LPS) for 6 hr. N = 6; unpaired Student’s t-test. *p ≤ 0.05; ***p ≤ 0.001.
The online version of this article includes the following source data and figure supplement(s) for figure 1:
Source data 1. Demographic and clinical parameters for entire cohort of healthy controls and patients with AH.
Source data 2. Demographic and clinical parameters for subset of healthy controls and patients with AH included
in TMA assay.
Source data 3. Liver flavin-containing monooxygenase 3 (FMO3) protein expression measured by Western blot
from healthy patients (HC) and patients with severe alcohol-associated hepatitis (AH) undergoing emergency liver
transplant (Maddrey’s discriminant function 45–187).
Source data 4. Liver flavin-containing monooxygenase 3 (FMO3) protein expression measured by Western blot
from healthy patients (HC) and patients with severe alcohol-associated hepatitis (AH) undergoing emergency liver
transplant (Maddrey’s discriminant function 45–187).
Source data 5. Liver HSC70 protein expression measured by Western blot from healthy patients (HC) and patients
with severe alcohol-associated hepatitis (AH) undergoing emergency liver transplant (Maddrey’s discriminant
function 45–187).
Source data 6. Liver HSC70 protein expression measured by Western Blot from healthy patients (HC) and patients
with severe alcohol-associated hepatitis (AH) undergoing emergency liver transplant (Maddrey’s discriminant
function 45–187).
Figure supplement 1. Levels of trimethylamine (TMA)-related metabolites in alcohol-associated hepatitis (AH).

(Figure 3C-E). More importantly, as with IMC (Figure 2F–K), FMC treatment significantly protected
against ethanol-induced ALT elevations (Figure 3F), hepatic steatosis (Figure 3G and K), and reduced
total and esterified cholesterol levels without altering free cholesterol (Figure 3H–J). However, FMC
trended to reduce but did not significantly alter Tnfα expression (Figure 3L). To determine whether
these effects were generalizable in other models of ethanol-induced liver injury, we exposed control
and FMC-treated mice to a 10-day chronic model in which mice were allowed free access to a 5% vol/
vol (27% kcal) for 10 days (Figure 3—figure supplement 1). In this 5%–10-day ethanol feeding model
FMC treatment did not significantly alter food intake, body weight, or blood ethanol levels, but was
able to selectively suppress TMA and TMAO levels (Figure 3—figure supplement 1). FMC treatment in the 5%–10-day model significantly reduced plasma AST and ALT levels, and trended toward
lowering liver triglycerides (Figure 3—figure supplement 1). However, in this short-term model there
were no apparent differences in hepatic cytokine/chemokine gene expression with either ethanol
exposure or FMC treatment (Figure 3—figure supplement 1 and data not shown). Collectively, these
data demonstrate that gut microbe-targeted choline TMA lyase inhibition with two structurally distinct
inhibitors (IMC or FMC) can generally protect mice against ethanol-induced liver injury.

Microbial choline TMA lyase inhibitors promote remodeling of the
gut microbiome and host liver transcriptome in an ethanol-dependent
manner
One theoretical advantage of the selective microbe-targeted choline TMA lyase inhibitors, compared
to antibiotic or MAMP-PRR-targeted therapies, is that they are anticipated to exert less selective
pressure for development of drug resistance given their non-lethal nature. However, microbes that
preferentially utilize choline as a carbon or nitrogen source might be anticipated to have reduced
competitive advantage in the presence of the inhibitor. We therefore next examined whether IMC or
FMC treatment was associated with alterations in choline utilizers and other members of the murine
gut microbiome community that are known to be correlated with ethanol-induced liver injury (Chen
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Figure 2. Small molecule choline trimethylamine (TMA) lyase inhibition with iodomethylcholine (IMC) protects mice against ethanol-induced liver
injury. Nine- to eleven-week-old female C57BL6/J mice were fed either ethanol-fed or pair-fed in the presence and absence of IMC as described in the
methods. Plasma levels of TMA (A), trimethylamine N-oxide (TMAO) (B), choline (C), carnitine (D), and betaine (E) were measured by mass spectrometry
(n = 4–5). Plasma alanine aminotransferase (ALT) (F) was measured enzymatically (n = 4–5). Liver triglycerides (G), total cholesterol (H), cholesterol esters
(I), and free cholesterol (J) were measured enzymatically (n = 4–5). (K) Representative H&E staining of livers from pair and EtOH-fed mice in the presence
and absence of IMC. (L) Hepatic messenger RNA levels of tumor necrosis factor alpha (Tnfα). Statistics were completed by a two-way analysis of variance
(ANOVA) followed by a Tukey’s multiple comparison test. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. All data are presented as mean ± SEM,
unless otherwise noted.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Small molecule inhibition with iodomethylcholine (IMC), but not fluoromethylcholine (FMC), reduces food intake in ethanol-fed
mice.
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Figure 3. Small molecule choline trimethylamine (TMA) lyase inhibition with fluoromethylcholine (FMC) protects mice against ethanol-induced liver
injury. Nine- to eleven-week-old female C57BL6/J mice were fed either ethanol-fed or pair-fed in the presence and absence of FMC as described in the
methods. Plasma levels of TMA (A), trimethylamine N-oxide (TMAO) (B), choline (C), carnitine (D), and betaine (E) were measured by mass spectrometry
(n = 3–5). Plasma alanine aminotransferase (ALT) (F) were measured at necropsy (n = 4–5). Liver triglycerides (G), total cholesterol (H), cholesterol esters
(I), and free cholesterol (J) were measured enzymatically (n = 4–5). (K) Representative H&E staining of livers from pair and EtOH-fed mice in the presence
and absence of FMC. (L) Hepatic messenger RNA levels of tumor necrosis factor alpha (Tnfα). Statistics were completed by a two-way analysis of
variance (ANOVA) followed by a Tukey’s multiple comparison test. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. All data are presented as mean ±
SEM, unless otherwise noted.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Small molecule inhibition of gut microbial trimethylamine (TMA) lyase activity with fluoromethylcholine (FMC) in a second model
of ethanol-induced liver injury.
Figure supplement 2. A single bolus of ethanol does not significantly alter trimethylamine (TMA) or trimethylamine N-oxide (TMAO) levels in mice.
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et al., 2011; Yan et al., 2011; Mutlu et al., 2009; Mutlu et al., 2012; Tripathi et al., 2018; Ciocan
et al., 2018; Llopis et al., 2016; Duan et al., 2019; Smirnova et al., 2020; Gao et al., 2019; Puri
et al., 2018; Lang and Schnabl, 2020). It is important to note that both IMC (Figure 4A–E) and FMC
(Figure 4F–J) altered the gut microbiome, with some consistent, yet several distinct differences. Non-
metric multidimensional scaling (NMDS) of microbial taxa revealed distinct clusters, indicating that
both IMC and FMC promoted clear restructuring of the cecal microbiome in an ethanol-dependent
manner (Figure 4A and F). Under pair-feeding conditions, both IMC and FMC caused a reciprocal
decrease in the relative abundance of Bacteroidetes and increase in Firmicutes (Figure 4B and G).
However, under ethanol-fed conditions IMC resulted in increased Bacteroidetes and reduced Firmicutes, and FMC treatment resulted in more modest reductions in Bacteroidetes and increased Firmicutes (Figure 4B and G). When examining drug-specific alterations at the genus level, we found that
under both pair- and ethanol-fed conditions, IMC treatment promoted significant increases in Faecalibaculum and Escherichica/Shigella, and reductions in Bacteroidales_S24-7 (Figure 4C–E , and H–I).
FMC, however, most significantly altered Turicibacter, Oscillibacter, and Lachnospiraceae, and it is
important to note that these FMC-induced alterations were different between pair- and ethanol-fed
groups (Figure 4C–E , and H–I). Collectively, these data demonstrate that inhibition of gut microbial
choline to TMA transformation with a selective non-lethal small molecule inhibitor promotes restructuring of the gut microbiome in an ethanol-dependent manner.
To more globally understand the effects of choline TMA lyase inhibitors on the host liver, we
performed unbiased RNA sequencing in mice undergoing pair or ethanol feeding treated either with
or without IMC (Figure 5). NMDS and hierarchical clustering analysis showed clear separation between
all four groups (Figure 5A and B). In pair-fed mice, IMC treatment caused significant decreases in
several genes encoding major urinary proteins (Mup2, Mup10, Mup11, and Mup18) and cytochrome
p450 enzymes (Cyp3a16, Cyp3a44), while increasing other genes involved in xenobiotic metabolism
(Ephx1, Cyp4a31) and hormone/cytokine signaling (Lepr, Fgf21, Il22ra1) (Figure 5C). Under ethanol-
feeding conditions, IMC treatment most significantly altered genes involved in hepatocyte metabolism (Cyp8b1, Ugt1a5, Pnpla5, Sult2a8, Ces3a, and Cmah), RNA processing (Ddx21, Ftsj3, Dus1l,
and Cmah), and again major urinary proteins (Mup2, Mup10, Mup11, and Mup20) (Figure 5D and E).
These unbiased RNASeq data demonstrate that gut microbe-targeted choline TMA lyase inhibitors
can alter the host liver transcriptome in an ethanol feeding-dependent manner.

The microbe-derived metabolite TMA elicits rapid hormone-like
signaling effects in mouse liver
The gut microbe-
derived co-
metabolites TMA and TMAO are generated postprandially in both
rodents and humans after a substrate-rich meal is ingested (Schugar et al., 2018; Boutagy et al.,
2015). Given the acute meal-related production and recent identification of candidate host receptors
for TMA (Li et al., 2013; Wallrabenstein et al., 2013) and TMAO (Chen et al., 2019), we hypothesized that TMA may be acting as a gut microbe-derived hormone to promote liver injury. However,
currently nothing is known regarding the acute hormone-like signaling effects stimulated by TMA in
the liver. To address this gap, we infused TMA directly into the portal circulation draining the gut (i.e.
portal vein) of fasted mice and examined global phosphorylation events stimulated in the liver 10 min
later using a phosphoproteomics approach (Figure 6A). It is important to note that this experiment
provided high levels of exogenous TMA via direct injection, and future studies should focus on more
physiologically relevant modes of TMA production like provision of gut bacteria that can naturally or
be genetically engineered to produce high levels. A total of 36 liver proteins exhibited site-specific
hypo- or hyper-phosphorylation 10 min after administration of TMA relative to vehicle-injected mice
(Figure 6B). Several of the TMA-driven phosphorylation events represented proteins that are enriched
in key hormonal signaling pathways known to impact hepatic metabolism. For example, portal vein
infusion of TMA resulted in altered phosphorylation of proteins implicated in protein kinase A (PKA)
signaling, including A kinase anchor protein 1 (AKAP1) (Huang et al., 1999) and FK506-binding protein
15 (FKBP15) (Nooh and Bahouth, 2017), and insulin signaling including insulin receptor substrate 2
(IRS2) (Araki et al., 1994; Figure 6B–D). TMA infusion was also associated with altering the phosphorylation of several guanine nucleotide exchange factors (GEF), including Rac/Cdc42 guanine nucleotide exchange factor 6 (Arhgef6) and Rho GTPase activating protein 17 (ARHGAP17) (Zhou et al.,
2016; Aslan, 2019), and proteins involved in RNA processing/splicing including signal recognition
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Figure 4. Small molecule choline trimethylamine (TMA) lyase inhibition promotes remodeling of the gut microbiome in an ethanol-dependent manner.
Nine- to eleven-week-old female C57BL6/J mice were fed either ethanol-fed or pair-fed in the presence and absence of iodomethylcholine (IMC)
or fluoromethylcholine (FMC) as described in the methods. (A) Non-metric multidimensional scaling (NMDS) plots based on the Bray-Curtis index
between the pair, EtOH, pair + 0.06% IMC, and EtOH + 0.06% IMC groups, Statistical analysis was performed with permutational multivariate analysis
of variance (PERMANOVA), and p-values are labeled in plots. R2 values are noted for comparisons with significant p-values and stand for percentage
variance explained by the variable of interest. (B) Boxplots of relative abundance patterns for Firmicutes and Bacteroidetes distinguishing pair, EtOH,
pair + 0.06% IMC and EtOH + 0.06% IMC groups. Statistical analysis was performed with Mann-Whitney U test (also called the Wilcoxon rank-sum
test, p-values are labeled in plots). Plotted are interquartile ranges (boxes), and dark lines in boxes are medians. (C) Stacked bar charts of relative
abundance (left y-axis) of the top 20 genera assembled across all four groups (pair, EtOH, pair + 0.06% IMC, and EtOH + 0.06% IMC groups). Pairwise
Figure 4 continued on next page
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differential abundance analyses between (D) pair-fed and pair-fed + 0.06% IMC and (E) EtOH-fed and EtOH-fed + 0.06% IMC group. Statistical analysis
was performed with White’s non-parametric t-test (p-values are labeled in plots). (F) NMDS plots based on the Bray-Curtis index between the pair,
EtOH, pair + 0.006% FMC, and EtOH + 0.006% FMC groups, Statistical analysis was performed with permutational multivariate analysis of variance
(PERMANOVA), and p-values are labeled in plots. R2 values are noted for comparisons with significant p-values and stand for percentage variance
explained by the variable of interest. (G) Boxplots of relative abundance patterns for Firmicutes and Bacteroidetes distinguishing pair, EtOH, pair +
0.006% FMC, and EtOH + 0.006% FMC groups. Statistical analysis was performed with Mann-Whitney U test (also called the Wilcoxon rank-sum test,
p-values are labeled in plots). Plotted are interquartile ranges (boxes), and dark lines in boxes are medians. (H) Stacked bar charts of relative abundance
(left y-axis) of the top 20 genera assembled across all four groups (pair, EtOH, pair + 0.06% FMC, and EtOH + 0.006% FMC groups). Pairwise differential
abundance analyses between (I) pair-fed and pair-fed + 0.06% FMC, and (J) EtOH-fed and EtOH-fed + 0.006% FMC group. Statistical analysis was
performed with White’s non-parametric t-test (p-values are labeled in plots).

particle 14 (SRP14) (Strub and Walter, 1990) and serine- and arginine-rich splicing factor 1 (SRSF1)
(Cho et al., 2011; Figure 6B and C). These data have identified acute TMA-driven signaling events
in the liver in vivo, and potentially link TMA to acute alterations in PKA-, insulin-, and GEF-driven
signaling cascades that deserve further exploration.

Discussion
Although drug discovery has historically targeted pathways in the human host, there is untapped
potential in therapeutically targeting the gut microbial endocrine organ to treat advanced liver
disease. This paradigm shift is needed in light of the clear and reproducible associations between the
gut microbiome in viral, alcohol-associated, and non-alcohol-associated liver diseases (Chen et al.,
2011; Yan et al., 2011; Mutlu et al., 2009; Mutlu et al., 2012; Tripathi et al., 2018; Ciocan et al.,
2018; Llopis et al., 2016; Duan et al., 2019; Smirnova et al., 2020; Gao et al., 2019; Puri et al.,
2018; Lang and Schnabl, 2020; Wilkinson et al., 1974; Tarao et al., 1979; Uesugi et al., 2001; Paik
et al., 2003; DeSantis et al., 2013; Knorr et al., 2020; Brown and Hazen, 2015). Now we are faced
with both the challenge and opportunity to test whether microbe-targeted therapeutic strategies
can improve health in the human metaorganism without negatively impacting the symbiotic relationships between microbes and host. Although traditional microbiome manipulating approaches such as
antibiotics, prebiotics, probiotics, and fecal microbial transplantation have shown their own unique
strengths and weaknesses, each of these presents unique challenges particularly for use in chronic
diseases such as end stage liver disease. As we move toward selective non-lethal small molecule therapeutics, the goal is to have exquisite target selectivity and limited systemic drug exposure given that
the targets are microbial in nature. This natural progression parallels the paradigm shifts in oncology
which have transitioned from broadly cytotoxic chemotherapies to target-selective small molecule
and biologics-based therapeutics. Here, we provide the first evidence that the gut microbial choline
metabolite TMA is elevated in the plasma of patients with AH, which corroborates previous reports
showing that TMA is also prominent in the breath of patients with AH (Hanouneh et al., 2014). Hence,
further studies are warranted to determine whether combined measures of breath and blood TMA
can serve as a prognostic biomarker to accurately predict AH-related mortality. Here, we also show
for the first time that a selective non-lethal small molecule drug that reduces bacterial production of
TMA can prevent ethanol-induced liver injury in mice. We also demonstrate that direct administration
of TMA can elicit rapid signaling effects in the liver, supporting the notion that gut microbial metabolites produced postprandially can act in an endocrine-like manner to alter host signal transduction and
associated disease pathogenesis. Collectively, these studies suggest that selective drugs targeting the
gut microbial TMA pathway may hold promise for treating AH.
As drug discovery advances in the area of small molecule non-lethal bacterial enzyme inhibitors, it is
key to understand how these drugs impact microbial ecology in the gut and other microenvironments.
As we have previously reported (Roberts et al., 2018; Gupta et al., 2020; Organ et al., 2020), gut
microbe-targeted choline TMA lyase inhibitors (IMC and FMC) induced a significant remodeling of the
cecal microbiome in mice. In the current studies there were some consistent, but many different cecal
microbiome alterations when comparing IMC and FMC (Figure 4), yet both drugs similarly improved
ethanol-induced liver injury. As small molecule bacterial enzymes inhibitors are developed, it will be
extremely important to understand their effects on microbial ecology, and it is expected that some
of the beneficial effects of these drugs will indeed originate from the restructuring of gut microbiome
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Figure 5. Small molecule choline trimethylamine (TMA) lyase inhibition with iodomethylcholine (IMC) alters the hepatic transcriptome in response to
ethanol. Nine- to eleven-week-old female C57BL6/J mice were fed either ethanol-fed or pair-fed in the presence and absence of IMC as described in
the methods. RNA was isolated from the livers and subjected to next-generation sequencing. (A) Non-metric multidimensional scaling (NMDS) plots;
each point represents a single sample from a single mouse. Positions of points in space display dissimilarities in the transcriptome, with points further
from one another being more dissimilar. (B–C) Row-normalized expression for the top 25 DEGs shown by heat map (B) while the volcano plot (C)
summarizes log2 fold changes vs. significance in response to IMC treatment in pair (left) and ethanol (right) feeding (n = 4). (D) Summary of significantly
differentially regulated pathways in mice treated with IMC in the ethanol-fed mice (n = 4).

communities. In fact, this is not an uncommon mechanism by which host targeted drugs impact human
health. A recent study showed that nearly a quarter of commonly used host-targeted drugs have
microbiome-altering properties (Maier et al., 2018), and in the context of diabetes therapeutics it is
important to note metformin’s anti-diabetic effects are partially mediated by the drug’s microbiome
altering properties (Wu et al., 2017). Given the strong association between gut microbiome and liver
disease (Chen et al., 2011; Yan et al., 2011; Mutlu et al., 2009; Mutlu et al., 2012; Tripathi et al.,
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Figure 6. Trimethylamine (TMA) rapidly reorganizes liver signal transduction in vivo. (A) Schematic of experiment; female C57BL/6 mice were fasted
overnight (12 hr fast), and then injected directly into the portal vein with vehicle (saline), or TMA, and only 10 min later liver tissue was harvested
for phosphoproteomic analysis to identify TMA-responsive phosphorylation events in mouse liver (n = 4 per group). (B) List of proteins that were
differentially phosphorylated (p < 0.05) upon TMA administration in vivo. (C) A doubly charged ion was present in the phospho-enriched sample
Figure 6 continued on next page
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that was identified as the KSpSVEGLEPAENK from signal recognition particle 14 kDa protein (Srp14). The CID spectra of this ion is dominated by
H3PO4 loss from the precursor ion consistent with the presence of a pS or pT residue. The mass difference between the y11 and y10 ions is consistent
with modification at S45. The observed chromatograms for this peptide from the saline and TMA samples are shown and the TMA/saline ratio
was determined to be 3.6 (p-value 0.0114). (D) A doubly charged ion was present in the phospho-enriched sample that was identified as the
RLpSEEACPGVLSVAPTVTQPPGR from A-kinase anchor protein 1. The CID spectra of this ion is dominated by fragmentation C-terminal to the proline
residues. The mass of the b7 ion is consistent with modification at S55. The observed chromatograms for this peptide from the saline and TMA samples
are shown and the TMA/saline ratio was determined to be 0.4.

2018; Ciocan et al., 2018; Llopis et al., 2016; Duan et al., 2019; Smirnova et al., 2020; Gao et al.,
2019; Puri et al., 2018; Lang and Schnabl, 2020; Wilkinson et al., 1974; Tarao et al., 1979; Uesugi
et al., 2001; Paik et al., 2003; DeSantis et al., 2013; Knorr et al., 2020; Brown and Hazen, 2015;
Gilbert et al., 2018), it may prove advantageous to find therapeutics that beneficially remodel the gut
microbiome as well as engage either their microbe or host target of interest.
The metaorganismal TMA/TMAO pathway represents only one of many microbial metabolic circuits
that have been associated with human disease (Figure 7). In fact, many microbe-associated metabolites such as short chain fatty acids, secondary bile acids, phenolic acids, polyamines, and others have
more recently been associated with many human diseases (Brown and Hazen, 2015; Gilbert et al.,
2018). In an ethanol- and meal-related manner, gut microbes produce a diverse array of metabolites
that reach micromolar to millimolar concentrations in the blood, making the collective gut microbiome
an active endocrine organ (Brown and Hazen, 2015). Small molecule metabolites are well known to
be mediators of signaling interactions in the host, and this work provides evidence that diet/ethanol-
microbe-host metabolic interplay can be causally linked to ethanol-induced liver injury. Our work, and
that of many others, demonstrates that there is clear evidence of bi-directional crosstalk between
the gut microbial endocrine organ and host liver metabolism. As drug discovery advances, it will be
important to move beyond targets based solely in the human host. This work highlights that non-
lethal gut microbe-targeted enzyme inhibitors may serve as effective therapeutics in AH and provides
proof of concept that this may be a generalizable approach to target metaorganismal crosstalk in
other disease contexts. In fact, selective inhibition of bacterial enzymes has the advantage over host
targeting given that small molecules can be designed to avoid systemic absorption and exposure,
thereby minimizing potential host off target effects. As shown here with the gut microbial TMA/TMAO
pathway, it is easy to envision that other microbe-host interactions are mechanistically linked to host
disease pathogenesis, serving as the basis for the rational design of microbe-targeted therapeutics
that improve human health.

Key resources table
Reagent type
(species) or
resource

Methods

Designation

Source or reference

Identifiers

Additional information

Strain, strain
background Mice
(Females)
9–11 Weeks

Jackson Laboratories

C57BL6/J, RRID:IMSR_
JAX:000664

5–8 per study

Biological
Plasma samples from
sample (Humans) 285 patients

Cleveland Clinic Foundation;
University of Louisville;
University of Massachusetts
Medical School; University of
Texas Southwestern Medical
Center

Not provided

Biological
Liver samples from five
sample (Humans) healthy donors

Clinical Resource for Alcoholic
Hepatitis Investigations at
Johns Hopkins University
Not provided

Liver samples from
Clinical Resource for Alcoholic
Biological
five patients with severe Hepatitis Investigations at
sample (Humans) AH
Johns Hopkins University
Not provided
Continued on next page
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Reagent type
(species) or
resource

Designation

Source or reference

Identifiers

Additional information

Antibody

Anti-FMO3 (Rabbit
monoclonal)

Abcam

Cat# ab126790, RRID:
AB_11128907

1:1000 (WB)

Antibody

Anti-HSC70 (Mouse
monoclonal)

Santa Cruz Biotechnology

Cat# sc-7298, RRID:
AB_627761

1:1000 (WB)

Antibody

Anti-rabbit IgG HRP

GE-Healthcare

Cat#: NA934-100UL, RRID:
AB_772206

1:5000 (WB)

Antibody

Anti-mouse IgG HRP

GE-Healthcare

NA931V, RRID: AB_772210

1:5000 (WB)

Sequence-based
reagent
Mouse Tnfα

Sigma

PCR primers

F:CCACCACGCTCTTCTGTCTAC
R:AGGGTCTGGGCCATAGAACT

Sequence-based
reagent
Mouse Il1β

Sigma

PCR primers

F:AGTTGACGGACCCCAAAAG
R:AGCTGGATGCTCTCATCAGG

Sequence-based
reagent
Mouse Fmo3

Sigma

PCR primers

F:CCCACATGCTTTGAGAGGAG
R:GGAAGAGTTGGTGAAGACCG

Sequence-based
reagent
Mouse Taar5

Sigma

PCR primers

F:AAAGAAAAGCTGCCAAGA
R:AAGGGAAGCCAACACACA

Sequence-based
reagent
Mouse CyclophilinA

Sigma

PCR primers

F:GCGGCAGGTCCATCTACG
R:GCCATCCAGCCATTCAGTC

Sequence-based
reagent
Mouse Cxcl1

IDT

PCR primers

F:TGCACCCAAACCGAAGTC
R:GTCAGAAGCCAGCGTTCACC

Sequence-based
reagent
Mouse Grp78

IDT

PCR primers

F:ACTTGGGGACCACCTATTCCT
R:ATCGCCAATCAGACGCTCC

Commercial
assay or kit

AST Commercial Kit

Sekisui Diagnostics

319–30

Commercial
assay or kit

ALT Commercial Kit

Sekisui Diagnostics

318–30

Commercial
assay or kit

Triglyceride Commercial
Kit
Wako

994–02891

Commercial
assay or kit

Total Cholesterol
Commercial Kit

Fisher Scientific

TR134321

Commercial
assay or kit

Free Cholesterol
Commercial Kit

Wako

993–02501

Commercial
assay or kit

RNAeasy Lipid Tissue
Mini Kit

Qiagen

74804

Commercial
assay or kit

Thermo Scientific Pierce
TiO2 Phosphopeptide
Enrichment and Clean-
up Kit
Fisher Scientific

PI88301

Commercial
assay or kit

RNAeasy Purification Kit Qiagen

74004

Chemical
Synthesized at the Cleveland
compound, drug Iodomethylcholine (IMC) Clinic

Not provided

Chemical
Fluoromethylcholine
compound, drug (FMC)

Synthesized at the Cleveland
Clinic

Not provided

Chemical
Trimethylamine
compound, drug Hydrochloride

Sigma

T72761

Chemical
compound, drug Lipopolysaccharide

Sigma

L4391

Continued on next page
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Reagent type
(species) or
resource

Designation

Source or reference

Identifiers

Software,
algorithm

GraphPad Prism

GraphPad Software, Inc

8.4

DADA2

https://benjjneb.
github.io/dada2/
dada-installation.html;
Callahan et al., 2016

1.16

Software,
algorithm

Phyloseq

https://www.bioconductor.
org/packages/release/
bioc/html/phyloseq.html

4.1, RRID:SCR_013080

Software,
algorithm

microbiomeSeq

https://github.com/
umerijaz/microbiomeSeq

1: RRID:SCR_002630

Ggplot2

https://cran.r-project.
org/web/
packages/
ggplot2/index.html

3.3.5, RRID:SCR_014601

Software,
algorithm

vegan

https://cran.r-project.org/web/
packages/
vegan/index.html
2.5–7

Other

Supersignal West Pico
Plus Substrate

Thermo Fisher

34577

Other

Diet

Dyets

710260

Software,
algorithm

Software,
algorithm

Additional information

Overview of human study populations
We made use of three different human study populations, detailed below, that included patients with
severities of AH/ALD. It must be noted that one limitation of our study is that each of these cohorts
used slightly different diagnostic criteria for defining the severity/stage of AH/ALD.

Human study populations and sample collection for TMA measurement
A total of 285 subjects were included in this study. De-identified plasma samples, along with clinical
and demographic data, were obtained from (1) the Northern Ohio Alcohol Center (NOAC) at the
Cleveland Clinic biorepository including 21 healthy individuals and 15 patients diagnosed and (2) the
Defeat Alcoholic Steatohepatitis (DASH) consortium (Cleveland Clinic, University of Louisville School of
Medicine, University of Massachusetts Medical School, and University of Texas Southwestern Medical
Center) including 249 patients with AH. Diagnosis with AH was performed using clinical and laboratory criteria, with MELD score utilized for distinguishing moderate (MELD < 20) and severe (MELD >
20) AH, as recommended by the NIAAA Alcoholic Hepatitis consortia (Crabb et al., 2016). A detailed
description of patient recruitment, inclusion and exclusion criteria for the DASH consortium has been
reported in previous studies (Vatsalya et al., 2020). Patients with AH were classified as moderate
(MELD < 20, n = 112) and severe (MELD ≥ 20, n = 152) according to the MELD score at admission
as part of either of two independent clinical trials (ClincalTrials.gov identifier # NCT01809132 and
NCT03224949) or the NOAC biorepository. These studies were approved by the Institutional Review
Boards of all four participating institutions and all study participants consented prior to collection of
data and blood samples. Clinical and demographic data for the entire cohort is presented in Figure
1—source data 1 and for the sub-set of subjects used for TMA analysis is presented in Figure 1—
source data 2.
In order to be able to measure volatile compounds such as TMA, blood was collected in EDTA-
coated tubes and immediately placed on ice. Plasma was separated by centrifugation at 1200× g for
15 min at 4°C. Plasma was rapidly acidified by adding 25 mL of 1 M hydrochloric acid (HCL) to 500 mL
of aliquoted plasma, followed by vigorous vortexing. Acidified plasma samples were stored at –80°C
in air-tight O-ring cryovials (Fisher Scientific, product # 02-681-373) until being processed for quantification of TMA and other volatile compounds. A non-acidified sample was also collected for standard
plasma biochemistries.
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Figure 7. Graphical summary depicting the proposed role of trimethylamine (TMA) in the progression of alcohol-associated liver disease (ALD). Gut
microbiota can elicit both metabolism-dependent and metabolism-independent effects in ALD. Relevant to this manuscript, intestinal microbes
metabolize dietary L-carnitine, choline, or phosphatidylcholine (PC) to form TMA, which is a volatile compound that originates exclusively from
gut bacterial metabolism and is elevated in ALD. Importantly, TMA can also be converted to trimethylamine N-oxide (TMAO) by hepatic flavin
monooxygenase 3 (FMO3), and TMAO has recently been linked to cardiovascular disease (CVD) promotion in humans. Metabolism-independent effects
are the result of gut hyperpermeability (leaky gut), allowing bacterial cell wall products such as lipopolysaccharide (LPS) and peptidoglycans to enter
into the blood stream and engage with host pattern recognition receptors (PRR) to promote hepatic inflammation. Collectively, metabolism-dependent
pathways such as TMA production as well as metabolism-independent pathways provide multiple bacterially derived ‘hits’ to promote ALD progression.
The small molecule bacterially targeted CutC/D inhibitors iodomethylcholine (IMC) and fluoromethylcholine (FMC) can effectively blunt ethanol-induced
liver injury in mice.

Analysis of hepatic FMO3 expression across different liver disease
etiologies
For data shown in main Figure 1 panel C, we leveraged access to publicly available bulk liver RNA
sequencing data from patients with different liver disease etiologies (Argemi et al., 2019). For this
cohort, early AH (EAH) was defined as MELD 7–8, severe AH with liver failure (AHL) with MELD 22–28,
and AHL with emergency liver transplant (ExAH) with MELD 18–21. All raw fastq files were downloaded from SRA (PRJNA531223) and dbGAP (phs001807.v1.p1) (Argemi et al., 2019). Fastq files
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were aligned to the human genome (GRCh38, indices downloaded from https://github.com/pachterlab/kallisto-transcriptome-indices/releases/download/ensembl-96/homo_sapiens.tar.gz; Pachter,
2018) using Kallisto version 0.44.0 with 100 bootstraps calculated (Bray et al., 2016). Data were then
merged with clinical data and analyzed with Sleuth in gene_mode with aggregation_column set to
Ensemble Gene ID; in addition, extra_bootstrap_summary and read_bootstrap_tpm were set to true
(Pimentel et al., 2017). Differential expression was measured with Sleuth using a cutoff of q < 0.05.

Human study populations and sample collection for liver Western
blotting
De-identified samples from five livers explanted from severe AH patients during liver transplantation
or five wedge biopsies from healthy donor livers were snap-frozen in liquid nitrogen and stored at
–80°C. Samples were provided by the Clinical Resource for Alcoholic Hepatitis Investigations at Johns
Hopkins University (R24 AA0025107, Z. Sun PI). Written informed consent was obtained from each
patient included in the study and the study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki as reflected in a priori approval by the Institutional Review Boards at Johns
Hopkins Medical Institutions. This cohort utilized Maddrey’s Discriminant Function as the primary
indicator of disease severity, with an average score of 102.5 ± 27.7. MELD scores are not available for
this cohort. Descriptive biochemical and clinical data for this cohort have been reported previously
(Tripathi et al., 2018).

Immunoblotting
Whole tissue homogenates were made from tissues in a modified RIPA buffer as previously described
(Warrier et al., 2015; Helsley et al., 2019; Schugar et al., 2017; Lord et al., 2016), and protein was
quantified using the bicinchoninic assay (Pierce). Proteins were separated by 4–12% SDS-PAGE, transferred to polyvinylidene difluoride membranes, and then proteins were detected after incubation with
specific antibodies as previously described (Warrier et al., 2015; Helsley et al., 2019; Schugar et al.,
2017; Lord et al., 2016) and listed in the Key resources table.

Real-time PCR analysis of gene expression
Tissue RNA extraction and qPCR analysis was performed as previously described (Helsley et al.,
2019). The mRNA expression levels were calculated based on the ΔΔ-CT method using cyclophilin A
as the housekeeping gene. qPCR was conducted using the Applied Biosystems 7500 Real-Time PCR
system. All primer sequences are listed in the Key resources table.

Chemical synthesis of gut microbe-targeted choline TMA lyase
inhibitors
The small molecule choline TMA lyase inhibitors IMC and FMC have been previously described as
potent and selective mechanism-based inhibitors targeted microbial CutC (Roberts et al., 2018).
Here, IMC and FMC were synthesized and structurally characterized as outlined below using both
multinuclear NMR analysis and high-
resolution mass spectrometry. 1H- and 13C-
NMR spectra for
IMC and FMC were recorded on a Bruker Ascend spectrometer operating at 400 MHz. Chemical
shifts are reported as parts per million (ppm). IMC iodide was prepared using a previously reported
method using 2-dimethylethanolamine and diiodomethane as reactants in acetonitrile followed by
recrystallization from dry ethanol. 1H- and 13C-NMRs of IMC were both consistent with that in the
reported literature (Mistry et al., 2002), as well as consistent based on proton and carbon chemical shift assignments indicated below. High-resolution MS corroborated the expected cation mass
and provided further evidence of structural identity. 1H-NMR (400 MHz, D2O): 5.24 (s, 2H, -N-CH2-I),
4.06–3.99 (m, 2H, -CH2-CH2-OH), 3.68–3.62 (m, 2H, -N-CH2-CH2-), 3.29 (s, 6H, -N(CH3)2); 13C-NMR (100
MHz, D2O): 66.1 (-CH2-CH2-OH), 55.8 (-N-CH2-CH2-), 52.9 (-N(CH3)2), 33.0 (-N-CH2-I); HRMS (ESI/TOF):
m/z (M+) calculated for C5H13INO, 230.0036; found, 230.0033. The synthesis of fluoromethylcholine
chloride was performed using the procedure below. 1H- and 13C-NMRs of FMC were consistent with
that in the reported literature (Gao et al., 2019). High-resolution MS was also consistent with the
expected cation mass. Chloro(fluoro)methane (2.05 kg, 29.9 mol, 6 eq) was bubbled into a solution
of 2-dimethylaminoethanol (444.0 g, 4.98 mol, 500 mL, 1 eq) in THF (1000 mL) at –70°C for 4 hr. The
mixture was then transferred to an autoclave and heated to 80°C and stirred for 18 hr (pressure:
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~15–50 psi). During this period, a white precipitate formed. The solid was isolated by filtration, washed
with cold THF (600 mL), and dried under vacuum to give fluoromethylcholine chloride as a white solid
(1.14 kg, 70.7% yield, 98.0% purity). 1H-NMR (400 MHz, D2O): 5.44 (s, 1H, -N-CH2-F), 5.32 (s, 1H,
-N-CH2-F), 4.04–3.98 (m, 2H, -CH2-CH2-OH), 3.60–3.54 (m, 2H, -N-CH2-CH2-), 3.19 (s, 6H, -N(CH3)2);
13
C-NMR (100 MHz, D2O): 97.8 and 95.6 (-N-CH2-F), 62.9 (-CH2-CH2-OH), 55.1 (-N-CH2-CH2-), 48.0
(-N(CH3)2); HRMS (ESI/TOF): m/z (M+) calculated for C5H13FNO (M+) 122.0976, found 122.0975.

Ethanol feeding trials in mice
All mice were maintained in an Association for the Assessment and Accreditation of Laboratory
Animal Care, International-approved animal facility. All experimental protocols were approved by
the Institutional Animal Care and Use Committee (IACUC) at the Cleveland Clinic. Age- and weight-
matched female C57BL6/J mice were randomized into pair- and ethanol-fed groups and adapted to
control liquid diet for 2 days. Two models of chronic ethanol feeding were used. (1) A 25-day chronic
model in which mice were allowed free access to increasing concentrations of ethanol for 25 days
(i.e. chronic feeding model) as previously described (McCullough et al., 2018). In this model, the
ethanol-fed mice were acclimated to ethanol as follows: 1% vol/vol for 2 days, 2% vol/vol for 2 days,
4% vol/vol (22% kcal) for 1 week, 5% vol/vol (27% kcal) for 1 week, and last 6% vol/vol (32% kcal) for
1 week and is denoted as 32%, day 25. (2) A 10-day chronic model in which mice were allowed free
access to a 5% vol/vol (27% kcal) for 10 days (Bertola et al., 2013). Ethanol-fed mice were allowed ad
libitum access to liquid diet. Control mice were pair-fed a diet that received isocalorically substituted
maltose dextrin for ethanol. Some cohorts received choline TMA lyase inhibitors IMC (0.06% wt/wt) or
FMC (0.006% wt/wt) in these liquid diets throughout the entire 10- to 25-day feeding period. Lieber-
DeCarli high-fat ethanol and control diets were purchased from Dyets (catalog number 710260; Bethlehem, PA).

LPS injections
Female C57BL6/J mice at 10.5 weeks of age were injected intraperitoneally with either 15 mg/kg LPS
(500 µg/mL, Sigma L4391) or a matched volume (30 mL/kg) of sterile saline. After 6 hr, mice were euthanized with ketamine/xylazine and the liver was immediately collected and homogenized in TRIzol.
RNA was extracted using chloroform phase separation and purified using Qiagen RNeasy kit.

Liver histology and immunohistochemistry
For histological analysis, formalin-fixed tissues were paraffin embedded, sectioned, and stained with
hematoxylin and eosin. Formalin-fixed samples are coded at the time of collection for blinded analysis.

Measurement of plasma aminotransferase levels
To determine the level of hepatic injury in mice, plasma was used to quantify ALT and AST levels using
a commercially available enzymatic assay (Sekisui Diagnostics, Lexington, MA) according to manufacturer’s instruction.

Measurement of hepatic lipid levels
Extraction of liver lipids and quantification of total plasma and hepatic triglycerides, cholesterol, and
cholesterol esters was conducted using enzymatic assays as described previously (Warrier et al.,
2015; Helsley et al., 2019; Schugar et al., 2017; Lord et al., 2016).

Quantification of TMA-related metabolites in acidified plasma
Stable isotope dilution high-performance liquid chromatography with on-line tandem mass spectrometry (LC-MS/MS) was used for quantification of levels of TMAO, TMA, choline, carnitine, betaine, and
γ-butyrobetaine in plasma, as previously described (Wang et al., 2014a). Their d9(methyl) isotopologues were used as internal standards. LC-MS/MS analyses were performed on a Shimadzu 8050
triple quadrupole mass spectrometer. IMC and d2-IMC, along with other metabolites, were monitored using multiple reaction monitoring of precursor and characteristic product ions as follows: m/z
230.0 → 58.0 for IMC; m/z 232.0 → 60.1 for d2-IMC; m/z 76.0 → 58.1 for TMAO; m/z 85.0 → 66.2 for
d9-TMAO; m/z 60.2 → 44.2 for TMA; m/z 69.0 → 49.1 for d9-TMA; m/z 104.0 → 60.1 for choline; m/z
113.1 → 69.2 for d9-choline; m/z 118.0 → 58.1 for betaine; m/z 127.0 → 66.2 for d9-betaine.
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Cecal microbiome analyses
16S rRNA amplicon sequencing were done for V4 region using via miSEQ from mouse cecal contents.
Raw 16S amplicon sequence and metadata were demultiplexed using split_libraries_fastq.py script
implemented in QIIME1.9.1 (Caporaso et al., 2010). Demultiplexed fastq file was split into sample
specific fastq files using 
split_
sequence_
file_
on_
sample_
ids.
py script from Qiime1.9.1 (Caporaso
et al., 2010). Individual fastq files without non-biological nucleotides were processed using Divisive
Amplicon Denoising Algorithm (DADA) pipeline (Callahan et al., 2016). The output of the dada2
pipeline (feature table of amplicon sequence variants [an ASV table]) was processed for alpha and beta
diversity analysis using phyloseq (McMurdie and Holmes, 2013), and microbiomeSeq (http://www.
github.com/umerijaz/microbiomeSeq) packages in R. Alpha diversity estimates were measured within
group categories using estimate_richness function of the phyloseq package (McMurdie and Holmes,
2013). Multidimensional scaling (also known as principal coordinate analysis [PCoA]) was performed
using Bray-Curtis dissimilarity matrix (Knorr et al., 2020) between groups and visualized by using
ggplot2 package (Wickham, 2009). We assessed the statistical significance (p < 0.05) throughout and
whenever necessary, we adjusted p-values for multiple comparisons according to the Benjamini and
Hochberg method to control false discovery rate (Benjamini, 2010) while performing multiple testing
on taxa abundance according to sample categories. We performed an analysis of variance (ANOVA)
among sample categories while measuring the of alpha diversity measures using plot_anova_diversity function in microbiomeSeq package (http://www.github.com/umerijaz/microbiomeSeq). Permutational multivariate analysis of variance (PERMANOVA) with 999 permutations was performed on
all principal coordinates obtained during PCoA with the ordination function of the microbiomeSeq
package. Wilcoxon (non-parametric) test was performed on ASV’s abundances against metadata variables levels using their base functions in R (Tilt, 1999).

RNA sequencing in mouse tissues
RNA sequencing libraries were generated from mouse liver using the Illumina mRNA TruSeq Directional library kit and sequenced using an Illumina HiSeq4000 (both according to the manufacturer’s
instructions). RNA sequencing was performed by the University of Chicago Genomics Facility, and data
analysis and data availability are described in detail in the online supplement. Briefly, RNA samples
were checked for quality and quantity using the Bio-analyzer (Agilent). RNA sequencing libraries were
generated using the Illumina mRNA TruSEQ Directional library kit and sequenced using an Illumina
HiSEQ4000 (both according to the manufacturer’s instructions). RNA sequencing was performed by
the University of Chicago Genomics Facility. Raw sequence files will be deposited in the Sequence
Read Archive before publication (SRA). Single-end 100 bp reads were trimmed with Trim Galore
(v.0.3.3, https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/. ) and controlled for quality
with FastQC (v0.11.3, http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc) before alignment to the
Mus musculus genome (Mm10 using UCSC transcript annotations downloaded July 2016). Reads
were aligned using the STAR alignerSTAR in single pass mode (v.2.5.2a_modified, RRID:SCR_004463,
https://github.com/alexdobin/STAR) with standard parameters. Raw counts were loaded into R
(http://www.R-project.org/) and edgeR was used to perform upper quantile, between-lane normalization, and DE analysis. Values generated with the cpm function of edgeR, including library size normalization and log2 conversion, were used in figures. Heat maps were generated of top 50 differentially
expressed transcripts using pheatmap. Reactome-based pathway analysis was performed using an
open-sourced R package: ReactomePA. RNA sequencing data have been deposited into the National
Institutes of Health (NIH)-sponsored GEO repository (accession number GSE157681).

Phosphoproteomics analyses to examine TMA-induced signaling events
in mouse liver
The goal of this experiment was to unbiasedly identify TMA-responsive signaling events in mouse liver
after an acute exposure (10 min) of TMA. To closely mimic physiological route of delivery, we delivered
saline or TMA directly into the portal vein in fasted mice. Briefly, C57BL/6 mice were fasted overnight
(12 hr fast), and between the hours of 9:00–10:00 am (2–3 hr into light cycle), mice were anesthetized
using isoflurane (4% for induction and 2% for maintenance). Once fully anesthetized, a midline laparotomy was performed, and the portal vein was visualized under a Leica M650 surgical microscope.
Briefly, a fresh 10 mM stock of trimethylamine hydrochloride (TMA-HCL) made in sterile saline, and the

Helsley, Miyata, Kadam, et al. eLife 2022;11:e76554. DOI: https://doi.org/10.7554/eLife.76554



20 of 28

Medicine

Research article

pH of stock solution was adjusted to 7.4. Mice then received 20 μL of either saline vehicle or TMA-HCL
via direct syringe infusion (Becton-Dickson product #309306); 9.75 min later a small aliquot (50 μL)
of portal blood was collected by pulling back on injection syringe left in place following injection. In
saline vehicle injected mice, portal blood levels of TMA ranged from 0.49 to 2.22 μM and TMAO levels
ranged from 2.53 to 7.14 μM. In mice injected with TMA-HCL, portal blood levels of TMA ranged
from 125.36 to 319.55 μM and TMAO levels ranged from 9.68 to 17.48 μM. Exactly 10 min after initial
injection, the liver was rapidly snap-frozen by immersion in liquid nitrogen. Liver samples were homogenized, the protein was precipitated with acetone, and the protein concentration was measured. A
total of 1 mg of protein from each sample was digested with trypsin and the resulting tryptic peptides
were subjected to phosphoserine and phosphothreonine enrichment using the Thermo Scientific
Pierce TiO2 Phosphopeptide Enrichment and Clean-up Kit (Fisher # PI88301). The enrichment was
performed based on the manufacturer’s instructions. The enriched peptide samples were subjected
to C18 clean-up prior to LC-MS analysis. The LC-MS system was a Finnigan LTQ-Obitrap Elite hybrid
mass spectrometer system. The HPLC column was a Dionex 15 cm × 75 µm id Acclaim Pepmap C18,
2 μm, 100 Å reversed-phase capillary chromatography column. Five μL volumes of the extract were
injected and the peptides eluted from the column by an acetonitrile/0.1% formic acid gradient at
a flow rate of 0.25 μL/min were introduced into the source of the mass spectrometer on-line. The
microelectrospray ion source is operated at 1.9 kV. The digest was analyzed using the data-dependent
multitask capability of the instrument acquiring full scan mass spectra to determine peptide molecular
weights and product ion spectra to determine amino acid sequence in successive instrument scans.
The LC-MS/MS data files were searched against the mouse UnitProtKB database (downloaded in
December 2019 contains 17,017 sequences) using Sequest bundled into Proteome Discoverer 2.4.
Cysteine carbamidomethylation was set as a fixed modification and oxidized methionine, protein
N-terminal acetylation, and phosphorylation of serine, threonine, and tyrosine were considered as
dynamic modification. A maximum of two missed cleavages were permitted. The peptide and protein
false discovery rates were set to 0.01 using a target-decoy strategy. Phosphorylation sites were identified using ptmRS node in PD2.4. The relative abundance of the positively identified phosphopeptides
was determined using the extracted ion intensities (Minora Feature Detection node) with Retention
time alignment. All peptides were included in the quantitation, the peptide intensities were normalized to total peptide amount. Missing values were imputed in Perseus using a normal distribution. A
total of 789 phosphopeptides were identified with 36 phosphopeptides determined to be two-fold
different in the TMA and saline samples with a p-value < 0.05 (t-test).

Statistical analysis
All statistical analyses were performed using GraphPad Prism and p < 0.05 was considered statistically
significant. All data are presented as mean ± SEM, unless otherwise noted in the figure legends. All
data were tested for equal variance and normality. For two-group comparison of parametric data,
a two-tailed Student’s t-test was performed, while non-parametric data were analyzed with Mann-
Whitney U test (also called the Wilcoxon rank-sum test). For studies comparing vehicle and TMA lyase
inhibitors in pair- and ethanol-fed mice, a two-way ANOVA was performed, followed by Tukey’s tests
for post hoc analysis. For human studies in AH patients, statistical significance was determined by
ANOVA and a Tukey’s honest significant difference post hoc test (p < 0.05).

Acknowledgements
This work was supported in part by National Institutes of Health grants P50 AA024333 (AJM, SD,
DSA, LEN, JMB), R01 DK120679 (JMB), P01 HL147823 (JMB, SLH), U01 AA026938 (LEN, JMB), P50
CA150964 (JMB), U01 AA021890 (LEN, SD), U01 AA021893 (SD, BB, CJM, MM, GS, and AJM), R01
HL103866 (SLH), R01 HL144651 (ZW), R01 HL130819 (ZW), U01 AA026980 (CJM), P50 AA 024337
(CJM), R21 AR 071046 (SD), R01 GM119174 (SD), R01 DK113196 (SD), R56 HL141744 (SD), U01
DK061732 (SD), U01 AA026977 (GS), UH3 AA026970 (GS), K99 AA028048 (AK), a Leducq Transatlantic
Networks of Excellence Award (SLH), a JSPS Overseas Research Fellowship 201960331 (TM), and the
American Heart Association (Postdoctoral Fellowships 17POST3285000 to RNH and 15POST2535000
to RCS). The Orbitrap Elite instrument used for proteomics was purchased via an NIH shared instrument grant 1S10RR031537 (BW).

Helsley, Miyata, Kadam, et al. eLife 2022;11:e76554. DOI: https://doi.org/10.7554/eLife.76554



21 of 28

Medicine

Research article

Additional information
Competing interests
Zeneng Wang: Kaiser Permanente (CME lecture sessions) Advisory Board for Incyte (on treatment
of cholangiocarcinoma). Stanley L Hazen: Z.W. report being named as co-inventor on pending and
issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics.
Z.W. reports being eligible to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Zehna Therapeutics, Cleveland Heart Lab, a wholly owned
subsidiary of Quest Diagnostics, and Procter & Gamble. The other authors declare that no competing
interests exist.
Funding
Funder

Grant reference number

Author

National Institutes of
Health

P50 AA024333

Arthur J McCullough
Srinivasan Dasarathy
Daniela S Allende
Laura E Nagy
Jonathan Mark Brown

National Institutes of
Health

R01 DK120679

Jonathan Mark Brown

National Institutes of
Health

P01 HL147823

Jonathan Mark Brown
Stanley L Hazen

National Institutes of
Health

U01 AA026938

Laura E Nagy
Jonathan Mark Brown

National Institutes of
Health

P50 CA150964

Jonathan Mark Brown

National Institutes of
Health

U01 AA021890

Laura E Nagy
Srinivasan Dasarathy

National Institutes of
Health

U01 AA021893

Srinivasan Dasarathy
Bruce Barton
Craig J McClain
Marko Mrdjen
Gyongyi Szabo
Arthur J McCullough

National Institutes of
Health

R01 HL103866

Stanley L Hazen

National Institutes of
Health

R01 HL144651

Zeneng Wang

National Institutes of
Health

R01 HL130819

Zeneng Wang

National Institutes of
Health

U01 AA026980

Craig J McClain

National Institutes of
Health

P50 AA 024337

Craig J McClain

National Institutes of
Health

R21 AR 071046

Srinivasan Dasarathy

National Institutes of
Health

R01 GM119174

Srinivasan Dasarathy

National Institutes of
Health

R01 DK113196

Srinivasan Dasarathy

National Institutes of
Health

R56 HL141744

Srinivasan Dasarathy

National Institutes of
Health

U01 DK061732

Srinivasan Dasarathy

Helsley, Miyata, Kadam, et al. eLife 2022;11:e76554. DOI: https://doi.org/10.7554/eLife.76554



22 of 28

Medicine

Research article
Funder

Grant reference number

Author

National Institutes of
Health

U01 AA026977

Gyongyi Szabo

National Institutes of
Health

UH3 AA026970

Gyongyi Szabo

National Institutes of
Health

K99 AA028048

Anagha Kadam

National Institutes of
Health

1S10RR031537

Belinda Willard

National Institutes of
Health

Leducq Transatlantic
Networks of Excellence
Award

Stanley L Hazen

JSPS Overseas Research
Fellowship

201960331

Tatsunori Miyata

American Heart
Association

17POST3285000

Robert N Helsley

American Heart
Association

15POST2535000

Rebecca C Schugar

The funders had no role in study design, data collection and interpretation, or the
decision to submit the work for publication.

Author contributions
Robert N Helsley, Chase Neumann, Lucas J Osborn, Rebecca C Schugar, Megan R McMullen, Annette
Bellar, Kyle L Poulsen, Adam Kim, Vai Pathak, Marko Mrdjen, James T Anderson, Belinda Willard,
Craig J McClain, Mack Mitchell, Arthur J McCullough, Svetlana Radaeva, Bruce Barton, Gyongyi
Szabo, Srinivasan Dasarathy, Jose Carlos Garcia-Garcia, Daniel M Rotroff, Zeneng Wang, Stanley
L Hazen, Laura E Nagy, Jonathan Mark Brown, Conceptualization, Data curation, Formal analysis,
Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing; Tatsunori Miyata,
Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing; Anagha Kadam, Data curation, Formal
analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing; Venkateshwari Varadharajan, Naseer Sangwan, Emily C Huang, Rakhee Banerjee, Amanda L Brown, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing
– review and editing; Kevin K Fung, Conceptualization, Data curation, Formal analysis, Investigation,
Methodology, Project administration, Supervision, Validation, Visualization, Writing – original draft,
Writing – review and editing; William J Massey, Conceptualization, Data curation, Formal analysis,
Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing; Danny Orabi, Conceptualization, Data curation, Formal analysis, Writing – original draft, Writing – review and editing; Daniela
S Allende, Data curation, Formal analysis, Methodology, Visualization, Writing – original draft, Writing
– review and editing
Author ORCIDs
Robert N Helsley  http://orcid.org/0000-0001-5000-3187
William J Massey  http://orcid.org/0000-0002-2087-6048
Bruce Barton  http://orcid.org/0000-0001-7878-8895
Srinivasan Dasarathy  http://orcid.org/0000-0003-1774-0104
Jonathan Mark Brown  http://orcid.org/0000-0003-2708-7487
Ethics
Clinical trial registration NCT01809132; NCT03224949.
Human subjects: Patients with AH were classified as moderate (MELD < 20, n=112) and severe (MELD
≥20, n=152) according to the MELD score at admission as part of either of two independent clinical
trials (ClincalTrials.gov identifier # NCT01809132 and NCT03224949) or the NOAC biorepository.
These studies were approved by the Institutional Review Boards of all 4 participating institutions

Helsley, Miyata, Kadam, et al. eLife 2022;11:e76554. DOI: https://doi.org/10.7554/eLife.76554



23 of 28

Medicine

Research article

and all study participants consented prior to collection of data and blood samples. Written informed
consent was obtained from each patient included in the study and the study protocol conforms to the
ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Institutional Review Boards at Johns Hopkins Medical Institutions.
All mice were maintained in an Association for the Assessment and Accreditation of Laboratory Animal
Care, International-approved animal facility. All experimental protocols were approved by the institutional animal care and use committee (IACUC) at the Cleveland Clinic.
Decision letter and Author response
Author response https://doi.org/10.7554/eLife.76554.sa2

Additional files
Supplementary files
•  Transparent reporting form
Data availability
Sequencing data have been deposited in GEO under accession code GSE157681.
The following dataset was generated:
Author(s)

Year

Brown JM, Helsley R, 2021
Kadam A, Neumann
C

Dataset title

Dataset URL

Database and Identifier

The Gut Microbe-Derived
Metabolite Trimethylamine
is a Biomarker of and
Therapeutic Target in
Alcohol-Associated Liver
Disease

http://www.ncbi.
nlm.nih.gov/geo/
query/acc.cgi?acc=
GSE157681

NCBI Gene Expression
Omnibus, GSE157681

References
Araki E, Lipes MA, Patti ME, Brüning JC, Haag B, Johnson RS, Kahn CR. 1994. Alternative pathway of insulin
signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186–190. DOI: https://doi.org/10.
1038/372186a0, PMID: 7526222
Argemi J, Latasa MU, Atkinson SR, Blokhin IO, Massey V, Gue JP, Cabezas J, Lozano JJ, Van Booven D, Bell A,
Cao S, Vernetti LA, Arab JP, Ventura-Cots M, Edmunds LR, Fondevilla C, Stärkel P, Dubuquoy L, Louvet A,
Odena G, et al. 2019. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in
alcoholic hepatitis. Nature Communications 10:3126. DOI: https://doi.org/10.1038/s41467-019-11004-3, PMID:
31311938
Ascha M, Wang Z, Ascha MS, Dweik R, Zein NN, Grove D, Brown JM, Marshall S, Lopez R, Hanouneh IA.
2016. Metabolomics studies identify novel diagnostic and prognostic indicators in patients with alcoholic
hepatitis. World Journal of Hepatology 8:499–508. DOI: https://doi.org/10.4254/wjh.v8.i10.499, PMID:
27057307
Asgharian H, Homayouni-Rad A, Mirghafourvand M, Mohammad-Alizadeh-Charandabi S. 2020. Effect of
probiotic yoghurt on plasma glucose in overweight and obese pregnant women: a randomized controlled
clinical trial. European Journal of Nutrition 59:205–215. DOI: https://doi.org/10.1007/s00394-019-01900-1,
PMID: 31069459
Aslan JE. 2019. Platelet Rho GTPase regulation in physiology and disease. Platelets 30:17–22. DOI: https://doi.
org/10.1080/09537104.2018.1475632, PMID: 29799302
Benjamini Y. 2010. Discovering the false discovery rate. Journal of the Royal Statistical Society 72:405–416. DOI:
https://doi.org/10.1111/j.1467-9868.2010.00746.x
Bertola A, Mathews S, Ki SH, Wang H, Gao B. 2013. Mouse model of chronic and binge ethanol feeding (the
NIAAA model). Nature Protocols 8:627–637. DOI: https://doi.org/10.1038/nprot.2013.032, PMID: 23449255
Boutagy NE, Neilson AP, Osterberg KL, Smithson AT, Englund TR, Davy BM, Hulver MW, Davy KP. 2015.
Short-term high-fat diet increases postprandial trimethylamine-N-oxide in humans. Nutrition Research (New
York, N.Y.) 35:858–864. DOI: https://doi.org/10.1016/j.nutres.2015.07.002, PMID: 26265295
Bray NL, Pimentel H, Melsted P, Pachter L. 2016. Near-optimal probabilistic RNA-seq quantification. Nature
Biotechnology 34:525–527. DOI: https://doi.org/10.1038/nbt.3519, PMID: 27043002
Brown JM, Hazen SL. 2015. The gut microbial endocrine organ: bacterially derived signals driving
cardiometabolic diseases. Annual Review of Medicine 66:343–359. DOI: https://doi.org/10.1146/annurev-med-
060513-093205, PMID: 25587655

Helsley, Miyata, Kadam, et al. eLife 2022;11:e76554. DOI: https://doi.org/10.7554/eLife.76554



24 of 28

Medicine

Research article

Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. 2016. DADA2: High-resolution sample
inference from Illumina amplicon data. Nature Methods 13:581–583. DOI: https://doi.org/10.1038/nmeth.3869,
PMID: 27214047
Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK,
Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD,
Pirrung M, Reeder J, et al. 2010. QIIME allows analysis of high-throughput community sequencing data. Nature
Methods 7:335–336. DOI: https://doi.org/10.1038/nmeth.f.303, PMID: 20383131
Cashman JR. 2002. Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical
metabolism. Pharmacogenomics 3:325–339. DOI: https://doi.org/10.1517/14622416.3.3.325, PMID: 12052141
Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, Wang Y, Zhu B, Li L. 2011. Characterization of fecal microbial
communities in patients with liver cirrhosis. Hepatology (Baltimore, Md.) 54:562–572. DOI: https://doi.org/10.
1002/hep.24423, PMID: 21574172
Chen S, Henderson A, Petriello MC, Romano KA, Gearing M, Miao J, Schell M, Sandoval-Espinola WJ, Tao J,
Sha B, Graham M, Crooke R, Kleinridders A, Balskus EP, Rey FE, Morris AJ, Biddinger SB. 2019. Trimethylamine
N-Oxide Binds and Activates PERK to Promote Metabolic Dysfunction. Cell Metabolism 30:1141-1151.. DOI:
https://doi.org/10.1016/j.cmet.2019.08.021, PMID: 31543404
Cho S, Hoang A, Sinha R, Zhong XY, Fu XD, Krainer AR, Ghosh G. 2011. Interaction between the RNA binding
domains of Ser-Arg splicing factor 1 and U1-70K snRNP protein determines early spliceosome assembly. PNAS
108:8233–8238. DOI: https://doi.org/10.1073/pnas.1017700108, PMID: 21536904
Ciocan D, Rebours V, Voican CS, Wrzosek L, Puchois V, Cassard AM, Perlemuter G. 2018. Characterization of
intestinal microbiota in alcoholic patients with and without alcoholic hepatitis or chronic alcoholic pancreatitis.
Scientific Reports 8:4822. DOI: https://doi.org/10.1038/s41598-018-23146-3, PMID: 29555983
Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, McClain C, McCullough A, Mitchell MC,
Morgan TR, Nagy L, Radaeva S, Sanyal A, Shah V, Szabo G, NIAAA Alcoholic Hepatitis Consortia. 2016.
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis:
Recommendation From the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology 150:785–790. DOI: https://
doi.org/10.1053/j.gastro.2016.02.042, PMID: 26921783
Craciun S, Balskus EP. 2012. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme.
PNAS 109:21307–21312. DOI: https://doi.org/10.1073/pnas.1215689109, PMID: 23151509
DeSantis DA, Ko CW, Liu Y, Liu X, Hise AG, Nunez G, Croniger CM. 2013. Alcohol-induced liver injury is
modulated by Nlrp3 and Nlrc4 inflammasomes in mice. Mediators of Inflammation 2013:751374. DOI: https://
doi.org/10.1155/2013/751374, PMID: 24453428
Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M, Shao Y, Liu J,
Hernandez-Morales A, Lessor L, Rahman IR, Miyamoto Y, Ly M, Gao B, Sun W, Kiesel R, et al. 2019.
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575:505–511. DOI: https://
doi.org/10.1038/s41586-019-1742-x, PMID: 31723265
Gao B, Lang S, Duan Y, Wang Y, Shawcross DL, Louvet A, Mathurin P, Ho SB, Stärkel P, Schnabl B. 2019. Serum
and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease. Digestive Diseases and Sciences 64:1878–
1892. DOI: https://doi.org/10.1007/s10620-019-05638-y, PMID: 31076986
Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. 2018. Current understanding of the human
microbiome. Nature Medicine 24:392–400. DOI: https://doi.org/10.1038/nm.4517, PMID: 29634682
Gupta N, Buffa JA, Roberts AB, Sangwan N, Skye SM, Li L, Ho KJ, Varga J, DiDonato JA, Tang WHW, Hazen SL.
2020. Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial
Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease. Arteriosclerosis, Thrombosis,
and Vascular Biology 40:1239–1255. DOI: https://doi.org/10.1161/ATVBAHA.120.314139, PMID: 32212854
Hanouneh IA, Zein NN, Cikach F, Dababneh L, Grove D, Alkhouri N, Lopez R, Dweik RA. 2014. The breathprints
in patients with liver disease identify novel breath biomarkers in alcoholic hepatitis. Clinical Gastroenterology
and Hepatology 12:516–523. DOI: https://doi.org/10.1016/j.cgh.2013.08.048, PMID: 24036050
Helsley RN, Varadharajan V, Brown AL, Gromovsky AD, Schugar RC, Ramachandiran I, Fung K, Kabbany MN,
Banerjee R, Neumann CK, Finney C, Pathak P, Orabi D, Osborn LJ, Massey W, Zhang R, Kadam A, Sansbury BE,
Pan C, Sacks J, et al. 2019. Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7)
drives non-alcoholic fatty liver disease. eLife 8:e49882. DOI: https://doi.org/10.7554/eLife.49882, PMID:
31621579
Huang LJ, Wang L, Ma Y, Durick K, Perkins G, Deerinck TJ, Ellisman MH, Taylor SS. 1999. NH2-Terminal targeting
motifs direct dual specificity A-kinase-anchoring protein 1 (D-AKAP1) to either mitochondria or endoplasmic
reticulum. The Journal of Cell Biology 145:951–959. DOI: https://doi.org/10.1083/jcb.145.5.951, PMID:
10352013
Knorr J, Wree A, Tacke F, Feldstein AE. 2020. The NLRP3 Inflammasome in Alcoholic and Nonalcoholic
Steatohepatitis. Seminars in Liver Disease 40:298–306. DOI: https://doi.org/10.1055/s-0040-1708540, PMID:
32526788
Kochanek K, Xu JQ, Arias E. 2017. Deaths: Final Data for 2017. National Vital Statistics Reports. National Center
for Health Statistics.
Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA,
Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WHW, et al. 2013. Intestinal microbiota
metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine 19:576–585. DOI:
https://doi.org/10.1038/nm.3145, PMID: 23563705

Helsley, Miyata, Kadam, et al. eLife 2022;11:e76554. DOI: https://doi.org/10.7554/eLife.76554



25 of 28

Medicine

Research article

Kwak DS, Jun DW, Seo JG, Chung WS, Park S-E, Lee KN, Khalid-Saeed W, Lee HL, Lee OY, Yoon BC, Choi HS.
2014. Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve
intestinal permeability in chronic liver disease. European Journal of Gastroenterology & Hepatology 26:1353–
1359. DOI: https://doi.org/10.1097/MEG.0000000000000214, PMID: 25244414
Lang S, Schnabl B. 2020. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. Cell Host
& Microbe 28:233–244. DOI: https://doi.org/10.1016/j.chom.2020.07.007, PMID: 32791115
Li Q, Korzan WJ, Ferrero DM, Chang RB, Roy DS, Buchi M, Lemon JK, Kaur AW, Stowers L, Fendt M, Liberles SD.
2013. Synchronous evolution of an odor biosynthesis pathway and behavioral response. Current Biology
23:11–20. DOI: https://doi.org/10.1016/j.cub.2012.10.047, PMID: 23177478
Llopis M, Cassard AM, Wrzosek L, Boschat L, Bruneau A, Ferrere G, Puchois V, Martin JC, Lepage P, Le Roy T,
Lefèvre L, Langelier B, Cailleux F, González-Castro AM, Rabot S, Gaudin F, Agostini H, Prévot S, Berrebi D,
Ciocan D, et al. 2016. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut
65:830–839. DOI: https://doi.org/10.1136/gutjnl-2015-310585, PMID: 26642859
Lord CC, Ferguson D, Thomas G, Brown AL, Schugar RC, Burrows A, Gromovsky AD, Betters J, Neumann C,
Sacks J, Marshall S, Watts R, Schweiger M, Lee RG, Crooke RM, Graham MJ, Lathia JD, Sakaguchi TF, Lehner R,
Haemmerle G, et al. 2016. Regulation of Hepatic Triacylglycerol Metabolism by CGI-58 Does Not Require
ATGL Co-activation. Cell Reports 16:939–949. DOI: https://doi.org/10.1016/j.celrep.2016.06.049, PMID:
27396333
Madjd A, Taylor MA, Mousavi N, Delavari A, Malekzadeh R, Macdonald IA, Farshchi HR. 2016. Comparison of
the effect of daily consumption of probiotic compared with low-fat conventional yogurt on weight loss in
healthy obese women following an energy-restricted diet: a randomized controlled trial. The American Journal
of Clinical Nutrition 103:323–329. DOI: https://doi.org/10.3945/ajcn.115.120170, PMID: 26702123
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H,
Patil KR, Bork P, Typas A. 2018. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature
555:623–628. DOI: https://doi.org/10.1038/nature25979, PMID: 29555994
Masarone M, Rosato V, Dallio M, Abenavoli L, Federico A, Loguercio C, Persico M. 2016. Epidemiology and
Natural History of Alcoholic Liver Disease. Reviews on Recent Clinical Trials 11:167–174. DOI: https://doi.org/
10.2174/1574887111666160810101202, PMID: 27515957
McCullough RL, McMullen MR, Sheehan MM, Poulsen KL, Roychowdhury S, Chiang DJ, Pritchard MT,
Caballeria J, Nagy LE. 2018. Complement Factor D protects mice from ethanol-induced inflammation and liver
injury. American Journal of Physiology. Gastrointestinal and Liver Physiology 315:G66–G79. DOI: https://doi.
org/10.1152/ajpgi.00334.2017, PMID: 29597356
McMurdie PJ, Holmes S. 2013. phyloseq: an R package for reproducible interactive analysis and graphics of
microbiome census data. PLOS ONE 8:e61217. DOI: https://doi.org/10.1371/journal.pone.0061217, PMID:
23630581
Mistry JS, Abraham DJ, Kozikowski AP, Hanin I. 2002. Neurochemistry of aging. 2. Design, synthesis and
biological evaluation of halomethyl analogs of choline with high affinity choline transport inhibitory activity.
Journal of Medicinal Chemistry 34:2031–2036. DOI: https://doi.org/10.1021/jm00111a016, PMID: 2066974
Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi M, Gillevet P. 2009. Intestinal dysbiosis: a possible
mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcoholism, Clinical and
Experimental Research 33:1836–1846. DOI: https://doi.org/10.1111/j.1530-0277.2009.01022.x, PMID:
19645728
Mutlu EA, Gillevet PM, Rangwala H, Sikaroodi M, Naqvi A, Engen PA, Kwasny M, Lau CK, Keshavarzian A. 2012.
Colonic microbiome is altered in alcoholism. American Journal of Physiology. Gastrointestinal and Liver
Physiology 302:G966–G978. DOI: https://doi.org/10.1152/ajpgi.00380.2011, PMID: 22241860
Nooh MM, Bahouth SW. 2017. Two barcodes encoded by the type-1 PDZ and by phospho-Ser312 regulate
retromer/WASH-mediated sorting of the ß1-adrenergic receptor from endosomes to the plasma membrane.
Cellular Signalling 29:192–208. DOI: https://doi.org/10.1016/j.cellsig.2016.10.014, PMID: 27816670
Organ CL, Li Z, Sharp TE, Polhemus DJ, Gupta N, Goodchild TT, Tang WHW, Hazen SL, Lefer DJ. 2020.
Nonlethal Inhibition of Gut Microbial Trimethylamine N-oxide Production Improves Cardiac Function and
Remodeling in a Murine Model of Heart Failure. Journal of the American Heart Association 9:e016223. DOI:
https://doi.org/10.1161/JAHA.119.016223, PMID: 32390485
Orman M, Bodea S, Funk MA, Campo AM-D, Bollenbach M, Drennan CL, Balskus EP. 2019. Structure-Guided
Identification of a Small Molecule That Inhibits Anaerobic Choline Metabolism by Human Gut Bacteria. Journal
of the American Chemical Society 141:33–37. DOI: https://doi.org/10.1021/jacs.8b04883, PMID: 30557011
Pachter LS. 2018. kallisto-transcriptome-indices. 944fbcc. Github. https://github.com/pachterlab/kallisto-
transcriptome-indices/releases
Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. 2003. Toll-like receptor 4 mediates
inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology (Baltimore,
Md.) 37:1043–1055. DOI: https://doi.org/10.1053/jhep.2003.50182, PMID: 12717385
Pimentel H, Bray NL, Puente S, Melsted P, Pachter L. 2017. Differential analysis of RNA-seq incorporating
quantification uncertainty. Nature Methods 14:687–690. DOI: https://doi.org/10.1038/nmeth.4324, PMID:
28581496
Puri P, Liangpunsakul S, Christensen JE, Shah VH, Kamath PS, Gores GJ, Walker S, Comerford M, Katz B,
Borst A, Yu Q, Kumar DP, Mirshahi F, Radaeva S, Chalasani NP, Crabb DW, Sanyal AJ, TREAT Consortium. 2018.
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. Hepatology
(Baltimore, Md.) 67:1284–1302. DOI: https://doi.org/10.1002/hep.29623, PMID: 29083504

Helsley, Miyata, Kadam, et al. eLife 2022;11:e76554. DOI: https://doi.org/10.7554/eLife.76554



26 of 28

Medicine

Research article

Reijnders D, Goossens GH, Hermes GDA, Neis EPJG, van der Beek CM, Most J, Holst JJ, Lenaerts K, Kootte RS,
Nieuwdorp M, Groen AK, Olde Damink SWM, Boekschoten MV, Smidt H, Zoetendal EG, Dejong CHC,
Blaak EE. 2016. Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans:
A Randomized Double-Blind Placebo-Controlled Trial. Cell Metabolism 24:63–74. DOI: https://doi.org/10.
1016/j.cmet.2016.06.016, PMID: 27411009
Roberts AB, Gu X, Buffa JA, Hurd AG, Wang Z, Zhu W, Gupta N, Skye SM, Cody DB, Levison BS, Barrington WT,
Russell MW, Reed JM, Duzan A, Lang JM, Fu X, Li L, Myers AJ, Rachakonda S, DiDonato JA, et al. 2018.
Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nature Medicine
24:1407–1417. DOI: https://doi.org/10.1038/s41591-018-0128-1, PMID: 30082863
Saha B, Tornai D, Kodys K, Adejumo A, Lowe P, McClain C, Mitchell M, McCullough A, Dasarathy S,
Kroll-Desrosiers A, Barton B, Radaeva S, Szabo G. 2019. Biomarkers of Macrophage Activation and Immune
Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis. Hepatology (Baltimore, Md.) 70:1134–1149.
DOI: https://doi.org/10.1002/hep.30617, PMID: 30891779
Schugar RC, Shih DM, Warrier M, Helsley RN, Burrows A, Ferguson D, Brown AL, Gromovsky AD, Heine M,
Chatterjee A, Li L, Li XS, Wang Z, Willard B, Meng Y, Kim H, Che N, Pan C, Lee RG, Crooke RM, et al. 2017.
The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of
White Adipose Tissue. Cell Reports 19:2451–2461. DOI: https://doi.org/10.1016/j.celrep.2017.05.077, PMID:
28636934
Schugar RC, Willard B, Wang Z, Brown JM. 2018. Postprandial gut microbiota-driven choline metabolism links
dietary cues to adipose tissue dysfunction. Adipocyte 7:49–56. DOI: https://doi.org/10.1080/21623945.2017.
1398295, PMID: 29172946
Smirnova E, Puri P, Muthiah MD, Daitya K, Brown R, Chalasani N, Liangpunsakul S, Shah VH, Gelow K,
Siddiqui MS, Boyett S, Mirshahi F, Sikaroodi M, Gillevet P, Sanyal AJ. 2020. Fecal Microbiome Distinguishes
Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity. Hepatology
(Baltimore, Md.) 72:271–286. DOI: https://doi.org/10.1002/hep.31178, PMID: 32056227
Strub K, Walter P. 1990. Assembly of the Alu domain of the signal recognition particle (SRP): dimerization of the
two protein components is required for efficient binding to SRP RNA. Molecular and Cellular Biology 10:777–
784. DOI: https://doi.org/10.1128/mcb.10.2.777-784.1990, PMID: 2153922
Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. 2013. Intestinal microbial metabolism
of phosphatidylcholine and cardiovascular risk. The New England Journal of Medicine 368:1575–1584. DOI:
https://doi.org/10.1056/NEJMoa1109400, PMID: 23614584
Tang WHW, Hazen SL. 2014. The contributory role of gut microbiota in cardiovascular disease. The Journal of
Clinical Investigation 124:4204–4211. DOI: https://doi.org/10.1172/JCI72331, PMID: 25271725
Tarao K, Moroi T, Nagakura Y, Ikeuchi T, Suyama T, Endo O, Fukushima K. 1979. Relationship between
endotoxaemia and protein concentration of ascites in cirrhotic patients. Gut 20:205–210. DOI: https://doi.org/
10.1136/gut.20.3.205, PMID: 437553
Tilt EM. 1999. Nonparametric statistical methods. Myles Hollander and Douglas A. Wolfe, Wiley, Chichester.
Statistics in Medicine 19:2-X. DOI: https://doi.org/10.1002/(SICI)1097-0258(20000530)19:103.0.CO;2-X
Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. 2018. The gut-liver axis and the
intersection with the microbiome. Nature Reviews. Gastroenterology & Hepatology 15:397–411. DOI: https://
doi.org/10.1038/s41575-018-0011-z, PMID: 29748586
Trøseid M, Ueland T, Hov JR, Svardal A, Gregersen I, Dahl CP, Aakhus S, Gude E, Bjørndal B, Halvorsen B,
Karlsen TH, Aukrust P, Gullestad L, Berge RK, Yndestad A. 2015. Microbiota-dependent metabolite
trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure.
Journal of Internal Medicine 277:717–726. DOI: https://doi.org/10.1111/joim.12328, PMID: 25382824
Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. 2001. Toll-like receptor 4 is involved in the mechanism
of early alcohol-induced liver injury in mice. Hepatology (Baltimore, Md.) 34:101–108. DOI: https://doi.org/10.
1053/jhep.2001.25350, PMID: 11431739
Vatsalya V, Cave MC, Kong M, Gobejishvili L, Falkner KC, Craycroft J, Mitchell M, Szabo G, McCullough A,
Dasarathy S, Radaeva S, Barton B, McClain CJ. 2020. Keratin 18 Is a Diagnostic and Prognostic Factor for
Acute Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology 18:2046–2054. DOI: https://doi.org/10.
1016/j.cgh.2019.11.050, PMID: 31811953
Wallrabenstein I, Kuklan J, Weber L, Zborala S, Werner M, Altmüller J, Becker C, Schmidt A, Hatt H, Hummel T,
Gisselmann G. 2013. Human trace amine-associated receptor TAAR5 can be activated by trimethylamine. PLOS
ONE 8:e54950. DOI: https://doi.org/10.1371/journal.pone.0054950, PMID: 23393561
Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung Y-M, Wu Y,
Schauer P, Smith JD, Allayee H, Tang WHW, DiDonato JA, Lusis AJ, Hazen SL. 2011. Gut flora metabolism of
phosphatidylcholine promotes cardiovascular disease. Nature 472:57–63. DOI: https://doi.org/10.1038/
nature09922, PMID: 21475195
Wang Z, Levison BS, Hazen JE, Donahue L, Li XM, Hazen SL. 2014a. Measurement of trimethylamine-N-oxide by
stable isotope dilution liquid chromatography tandem mass spectrometry. Analytical Biochemistry 455:35–40.
DOI: https://doi.org/10.1016/j.ab.2014.03.016, PMID: 24704102
Wang Z, Tang WHW, Buffa JA, Fu X, Britt EB, Koeth RA, Levison BS, Fan Y, Wu Y, Hazen SL. 2014b. Prognostic
value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide.
European Heart Journal 35:904–910. DOI: https://doi.org/10.1093/eurheartj/ehu002, PMID: 24497336
Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, Gu X, Huang Y, Zamanian-Daryoush M, Culley MK,
DiDonato AJ, Fu X, Hazen JE, Krajcik D, DiDonato JA, Lusis AJ, Hazen SL. 2015. Non-lethal Inhibition of Gut

Helsley, Miyata, Kadam, et al. eLife 2022;11:e76554. DOI: https://doi.org/10.7554/eLife.76554



27 of 28

Medicine

Research article

Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell 163:1585–1595. DOI: https://
doi.org/10.1016/j.cell.2015.11.055, PMID: 26687352
Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown AL, Marshall S, McDaniel A, Schugar RC,
Wang Z, Sacks J, Rong X, Vallim T, Chou J, Ivanova PT, Myers DS, Brown HA, Lee RG, Crooke RM, Graham MJ,
et al. 2015. The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol
Balance. Cell Reports 10:326–338. DOI: https://doi.org/10.1016/j.celrep.2014.12.036, PMID: 25600868
Wickham H. 2009. Ggplot2: Elegant Graphics for Data Analysis. New York, NY: Springer Publishing Company,
Incorporated. DOI: https://doi.org/10.1007/978-0-387-98141-3
Wilkinson SP, Arroyo V, Gazzard BG, Moodie H, Williams R. 1974. Relation of renal impairment and
haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet (London, England) 1:521–524.
DOI: https://doi.org/10.1016/s0140-6736(74)92711-1, PMID: 4131970
Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M,
Planas-Fèlix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R, Fernàndez-Real JM,
Bäckhed F. 2017. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes,
contributing to the therapeutic effects of the drug. Nature Medicine 23:850–858. DOI: https://doi.org/10.
1038/nm.4345, PMID: 28530702
Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, Tsukamoto H, Nelson KE, Brenner DA, Schnabl B.
2011. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology (Baltimore, Md.)
53:96–105. DOI: https://doi.org/10.1002/hep.24018, PMID: 21254165
Zhou W, Li X, Premont RT. 2016. Expanding functions of GIT Arf GTPase-activating proteins, PIX Rho guanine
nucleotide exchange factors and GIT-PIX complexes. Journal of Cell Science 129:1963–1974. DOI: https://doi.
org/10.1242/jcs.179465, PMID: 27182061
Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, Li L, Fu X, Wu Y, Mehrabian M, Sartor RB, McIntyre TM,
Silverstein RL, Tang WHW, DiDonato JA, Brown JM, Lusis AJ, Hazen SL. 2016. Gut Microbial Metabolite TMAO
Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell 165:111–124. DOI: https://doi.org/10.1016/j.cell.
2016.02.011, PMID: 26972052
Zhu W, Wang Z, Tang WHW, Hazen SL. 2017. Gut Microbe-Generated Trimethylamine N-Oxide From Dietary
Choline Is Prothrombotic in Subjects. Circulation 135:1671–1673. DOI: https://doi.org/10.1161/
CIRCULATIONAHA.116.025338, PMID: 28438808

Helsley, Miyata, Kadam, et al. eLife 2022;11:e76554. DOI: https://doi.org/10.7554/eLife.76554



28 of 28

